# TCF7L2

## Overview
TCF7L2, or transcription factor 7-like 2, is a gene that encodes a protein belonging to the T-cell factor/lymphoid enhancer factor (TCF/LEF) family, which plays a pivotal role in the Wnt/β-catenin signaling pathway. The protein, often referred to as TCF4, functions as a transcription factor, regulating the expression of numerous genes involved in cellular processes such as development, differentiation, and metabolism (Weise2009Alternative). TCF4 is characterized by its β-catenin binding domain and high-mobility group (HMG) box DNA-binding domain, which are essential for its role in gene regulation (Weise2009Alternative). The gene is subject to extensive alternative splicing, resulting in multiple isoforms that contribute to its functional diversity and tissue-specific activity (Weise2009Alternative). TCF7L2 has garnered significant attention due to its association with type 2 diabetes, with specific genetic variants linked to increased disease risk, highlighting its importance in metabolic regulation and potential as a therapeutic target (Groves2006Association; Ip2012The).

## Structure
The TCF7L2 gene encodes the TCF4 protein, a member of the T-cell factor family involved in the Wnt/β-catenin signaling pathway. The protein structure includes a β-catenin binding domain and an HMG-box DNA-binding domain, which are crucial for its function in gene regulation (Weise2009Alternative). TCF4 undergoes extensive alternative splicing, resulting in multiple isoforms with distinct domain compositions, such as TCF4E, TCF4M, and TCF4S. These isoforms differ in their C-terminal structures, affecting their promoter-binding and transcriptional activation properties (Weise2009Alternative).

Some TCF4 isoforms contain a C-clamp, an auxiliary DNA-binding domain, which influences their ability to bind specific TCF-binding elements. The presence or absence of the C-clamp and other variable regions due to alternative splicing contribute to the functional diversity of TCF4 isoforms (Weise2009Alternative). The TCF4E variants, for example, have a complete C-clamp and binding motifs for the transcriptional repressor CtBP, while TCF4M and TCF4S lack these features (Weise2009Alternative).

The structural diversity of TCF4 isoforms is crucial for their role in modulating Wnt/β-catenin signaling, allowing for tissue-specific responses and interactions with other proteins, such as HNF4α in liver cells (Neve2014Alternative).

## Function
The TCF7L2 gene encodes a transcription factor that is a key component of the WNT signaling pathway, which is crucial for various cellular processes, including cell development and regeneration. In healthy human cells, TCF7L2 functions as a site-specific DNA binding transcriptional regulator, influencing the expression of approximately 14,000 genes in a cell type-specific manner (Frietze2012Cell). It can act as both an activator and a repressor of gene expression, depending on the presence of CTNNB1 (beta-catenin) in the nucleus (Frietze2012Cell).

TCF7L2 plays a significant role in the regulation of insulin production and processing in pancreatic islets. It directly regulates proinsulin expression through Isl1 and Ins1, and indirectly through other transcription factors such as MafA, NeuroD1, and Pdx1 (Zhou2014TCF7L2). TCF7L2 is also involved in the regulation of the glucagon gene, which encodes glucagon-like peptide 1 (GLP1) in gut L cells, suggesting a role in incretin release or signaling pathways (Pearson2009Translating). The gene's activity affects the proinsulin-to-insulin ratio and the intracellular trafficking of insulin, highlighting its critical role in maintaining normal insulin function (Zhou2014TCF7L2).

## Clinical Significance
Mutations and variations in the TCF7L2 gene are significantly associated with an increased risk of type 2 diabetes. Single nucleotide polymorphisms (SNPs) such as rs7903146 and rs4506565 have been identified as strong genetic risk factors for the disease, with studies showing a substantial effect on individual risk (Groves2006Association; Peng2012TCF7L2). These genetic variations are linked to impaired beta-cell function and incretin resistance, which are critical in the pathogenesis of diabetes (Wagner2014Untangling). The TCF7L2 gene is involved in the Wnt signaling pathway, which plays a role in insulin secretion and glucose metabolism, further implicating its variants in diabetes susceptibility (Ip2012The).

The gene's expression and splicing patterns also have clinical significance. Alterations in TCF7L2 splicing, potentially influenced by SNPs, may lead to different transcript isoforms with distinct biological roles, affecting beta-cell function and mass (Mondal2010Genotype). Although the exact mechanisms remain unclear, these variations are thought to contribute to altered insulin secretion and glucose regulation, highlighting the gene's role in metabolic disorders (Osmark2009Unique). The association of TCF7L2 with type 2 diabetes has been replicated across various populations, underscoring its global clinical relevance (Ip2012The).

## Interactions
TCF7L2 interacts with various proteins and nucleic acids, playing a significant role in gene regulation. In MCF7 breast cancer cells, TCF7L2 is tethered to the genome by GATA3, leading to transcriptional repression. This interaction is crucial for the regulation of genes involved in breast cancer and cell differentiation (Frietze2012Cell). In HepG2 liver cells, TCF7L2 co-localizes with HNF4α and FOXA2, with about 50% of TCF7L2 sites shared by these factors, indicating direct binding to DNA at co-localizing sites (Frietze2012Cell). TCF7L2 isoforms T6 and T8 specifically interact with HNF4α, suggesting a unique role in regulating gluconeogenesis (Neve2014Alternative).

TCF7L2 also forms complexes with proteins such as PARP-1, DNA topoisomerase I, and ATP-dependent RNA helicase A at the SNP rs7903146 locus, which is associated with type 2 diabetes. These interactions suggest a regulatory complex that modulates TCF7L2 function (Xia2014Characterization). Additionally, TCF7L2 interacts with β-catenin, a key mediator of the Wnt signaling pathway, to activate downstream gene expression, highlighting its role in transcriptional regulation (Xia2014Characterization).


## References


[1. (Peng2012TCF7L2) Sihua Peng, Yimin Zhu, Bingjian Lü, Fangying Xu, Xiaobo Li, and Maode Lai. Tcf7l2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated meta-analysis involving 121 174 subjects. Mutagenesis, 28(1):25–37, December 2012. URL: http://dx.doi.org/10.1093/mutage/ges048, doi:10.1093/mutage/ges048. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/mutage/ges048)

[2. (Mondal2010Genotype) Ashis K. Mondal, Swapan K. Das, Giulia Baldini, Winston S. Chu, Neeraj K. Sharma, Oksana G. Hackney, Jianhua Zhao, Struan F. A. Grant, and Steven C. Elbein. Genotype and tissue-specific effects on alternative splicing of the transcription factor 7-like 2 gene in humans. The Journal of Clinical Endocrinology &amp; Metabolism, 95(3):1450–1457, March 2010. URL: http://dx.doi.org/10.1210/jc.2009-2064, doi:10.1210/jc.2009-2064. This article has 56 citations.](https://doi.org/10.1210/jc.2009-2064)

[3. (Osmark2009Unique) P. Osmark, O. Hansson, A. Jonsson, T. Rönn, L. Groop, and E. Renström. Unique splicing pattern of the tcf7l2 gene in human pancreatic islets. Diabetologia, 52(5):850–854, February 2009. URL: http://dx.doi.org/10.1007/s00125-009-1293-z, doi:10.1007/s00125-009-1293-z. This article has 58 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-009-1293-z)

[4. (Weise2009Alternative) Andreas Weise, Katja Bruser, Susanne Elfert, Britta Wallmen, Yvonne Wittel, Simon Wöhrle, and Andreas Hecht. Alternative splicing of tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at wnt/β-catenin targets. Nucleic Acids Research, 38(6):1964–1981, December 2009. URL: http://dx.doi.org/10.1093/nar/gkp1197, doi:10.1093/nar/gkp1197. This article has 157 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkp1197)

[5. (Pearson2009Translating) E. R. Pearson. Translating tcf7l2: from gene to function. Diabetologia, 52(7):1227–1230, April 2009. URL: http://dx.doi.org/10.1007/s00125-009-1356-1, doi:10.1007/s00125-009-1356-1. This article has 34 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-009-1356-1)

[6. (Wagner2014Untangling) Robert Wagner, Harald Staiger, Susanne Ullrich, Norbert Stefan, Andreas Fritsche, and Hans-Ulrich Häring. Untangling the interplay of genetic and metabolic influences on beta-cell function: examples of potential therapeutic implications involving tcf7l2 and ffar1. Molecular Metabolism, 3(3):261–267, June 2014. URL: http://dx.doi.org/10.1016/j.molmet.2014.01.001, doi:10.1016/j.molmet.2014.01.001. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.molmet.2014.01.001)

[7. (Zhou2014TCF7L2) Yuedan Zhou, Soo-Young Park, Jing Su, Kathleen Bailey, Emilia Ottosson-Laakso, Liliya Shcherbina, Nikolay Oskolkov, Enming Zhang, Thomas Thevenin, João Fadista, Hedvig Bennet, Petter Vikman, Nils Wierup, Malin Fex, Johan Rung, Claes Wollheim, Marcelo Nobrega, Erik Renström, Leif Groop, and Ola Hansson. Tcf7l2 is a master regulator of insulin production and processing. Human Molecular Genetics, 23(24):6419–6431, July 2014. URL: http://dx.doi.org/10.1093/hmg/ddu359, doi:10.1093/hmg/ddu359. This article has 150 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddu359)

[8. (Groves2006Association) Christopher J. Groves, Eleftheria Zeggini, Jayne Minton, Timothy M. Frayling, Michael N. Weedon, Nigel W. Rayner, Graham A. Hitman, Mark Walker, Steven Wiltshire, Andrew T. Hattersley, and Mark I. McCarthy. Association analysis of 6,736 u.k. subjects provides replication and confirms tcf7l2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes, 55(9):2640–2644, September 2006. URL: http://dx.doi.org/10.2337/db06-0355, doi:10.2337/db06-0355. This article has 200 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/db06-0355)

[9. (Xia2014Characterization) Qianghua Xia, Sandra Deliard, Chao-Xing Yuan, Matthew E Johnson, and Struan FA Grant. Characterization of the transcriptional machinery bound across the widely presumed type 2 diabetes causal variant, rs7903146, within tcf7l2. European Journal of Human Genetics, 23(1):103–109, March 2014. URL: http://dx.doi.org/10.1038/ejhg.2014.48, doi:10.1038/ejhg.2014.48. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2014.48)

[10. (Ip2012The) Wilfred Ip, Yu-ting Alex Chiang, and Tianru Jin. The involvement of the wnt signaling pathway and tcf7l2 in diabetes mellitus: the current understanding, dispute, and perspective. Cell &amp; Bioscience, August 2012. URL: http://dx.doi.org/10.1186/2045-3701-2-28, doi:10.1186/2045-3701-2-28. This article has 73 citations.](https://doi.org/10.1186/2045-3701-2-28)

[11. (Frietze2012Cell) Seth Frietze, Rui Wang, Lijing Yao, Yu Gyoung Tak, Zhenqing Ye, Malaina Gaddis, Heather Witt, Peggy J Farnham, and Victor X Jin. Cell type-specific binding patterns reveal that tcf7l2 can be tethered to the genome by association with gata3. Genome Biology, September 2012. URL: http://dx.doi.org/10.1186/gb-2012-13-9-r52, doi:10.1186/gb-2012-13-9-r52. This article has 95 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/gb-2012-13-9-r52)

[12. (Neve2014Alternative) Bernadette Neve, Olivier Le Bacquer, Sandrine Caron, Marlène Huyvaert, Audrey Leloire, Odile Poulain-Godefroy, Cécile Lecoeur, François Pattou, Bart Staels, and Philippe Froguel. Alternative human liver transcripts of tcf7l2 bind to the gluconeogenesis regulator hnf4α at the protein level. Diabetologia, 57(4):785–796, January 2014. URL: http://dx.doi.org/10.1007/s00125-013-3154-z, doi:10.1007/s00125-013-3154-z. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-013-3154-z)